First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF에 대한 매도 수량은 투자자에게 First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF (ARCA:FCFY), 공매도 수량 보고

Technology

Financial Services

Consumer Cyclical

Healthcare

Communication Services

Industrials

Consumer Defensive

Energy

Real Estate

Basic Materials

Utilities

The Fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the total return performance of the Index, which includes dividends paid by the common stocks in the Index. The Fund will generally employ a full replication strategy, meaning that it will normally invest in all of the securities comprising the Index in proportion to their weightings in the Index. The Index is owned and was developed by S&P Dow Jones Indices, LLC a division of S&P Global (SPDJI or the Index Provider). The Index Provider reserves the right to make exceptions when applying the methodology if the need arises to ensure that the Index continues to achieve its objective. In addition, the Index Provider may revise Index policy covering rules for selecting companies, treatment of dividends, share counts or other matters.

Hp Inc.

Skyworks Solutions Inc.

Hewlett Packard Enterprise Co.

Warner Bros. Discovery, Inc

Cisco Systems, Inc.

AT&T Inc.

Centene Corp.

Netapp Inc.

Cognizant Technology Solutions Corp. Class A

Electronic Arts, Inc.

First Trust S&P 500 Diversified Free Cash Flow ETF

Markets

ETFs

BKGI

CHAT

FCFY

Engine No. 1 ETF Trust Engine No. 1 Transform Climate ETF

NETZ

RJMG

UTES

미국의 두 인기 상장지수펀드(ETF)가 수요일에 S&amp;P 500 지수가 사상 최고치에 도달하면서 역대 최고가를 기록했다. S&amp;P 500 지수의 성과를 추적하여 약 500개의 대형주로 구성된 Vanguard S&amp;P 500 ETF(NYSE:VOO)는 미국 동부 시간 수요일 오전 10시 직후 527.23달러에 도달한 후 수요일 0.20% 하락한 525.61달러에 마감되었다.

VOO 대 VTI: S&amp;P 500이 사상 최고치를 기록하자 두 인기 상장지수펀드(ETF)도 최고점 도달

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF

Deutsche Bank analyst Scott Deuschle upgrades RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) from Sell to Hold, raising the<a target="_blank" href="https://www.benzinga.com/quote/RTX/analyst-ratings" rel="noreferrer noopener"> price forecast from&nbsp;$109&nbsp;to&nbsp;$129.</a>
According to the analyst, RTX&#8217;s aerospace exposure is expected to enable it to outpace other defense companies, leveraging operational efficiencies to drive long-term growth and compound earnings.
The analyst sees potential for further stock upside with RTX currently valued similarly to pure defense companies for 2026 but boasting a more promising long-term growth outlook due to its aerospace exposure.
Deuschle writes that the overall narrative for RTX is compelling, as long as operational improvements persist.
The analyst forecasts third-quarter earnings per share of $1.36, exceeding the Street&#8217;s expectation of $1.32 by $0.04.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41146781/rtxs-raytheon-secures-darpa-contract-to-develop-ultra-wide-bandgap-semiconductors-details" rel="noreferrer noopener">RTX&#8217;s Raytheon Secures DARPA Contract To Develop Ultra-Wide Bandgap Semiconductors: Details</a>
Deuschle projects sequential revenue growth at Pratt &amp; Whitney and Collins, driven by increased aftermarket activity at Pratt &amp; Whitney from higher V2500 and GTF shop visits, while Collins is likely to benefit from sequential original equipment growth on Airbus and business jet platforms, along with sustained aftermarket strength and potential upside from increased modification revenue.
The analyst projects Raytheon&#8217;s revenue will decline quarter-over-quarter but sees upside potential due to strong demand, favorable DoD spending trends, and gradually improving conditions in the defense supply chain.
EPS estimates for 2024-2026 have been revised to $5.48, $6.06, and $6.88, respectively, from $5.48, $6.17, and $6.93.
This decrease is mainly due to lower original equipment rate assumptions for both Boeing and Airbus, partially offset by a better product mix and higher margins.
Meanwhile, operational risk keeps them at a Hold rather than a Buy.
Price Action: RTX shares are trading lower by 0.52% to $123.40 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41170128/jobs-report-preview-could-september-labor-data-shift-feds-interest-rate-path" target="_blank" rel="noreferrer noopener">Jobs Report Preview: Could September Labor Data Shift Fed&#8217;s Interest Rate Path?</a></li>
</ul>

Analyst Color

Equities

News

Upgrades

Price Target

Analyst Ratings

Trading Ideas

General

European Aeronautic Defence And Space Unsponsored

EADSY

Deutsche Bank Changes Tune On Raytheon Parent RTX, Sees Aerospace Edge Fuel Long-Term Growth Potential

On Tuesday, Koninklijke Philips N.V.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) issued a correction related to the Software Version used in Trilogy Evo, Trilogy EV300, Trilogy Evo O2, and Trilogy Evo Universal ventilators to resolve safety issues that may affect the device&#8217;s ability to support patient breathing.
The FDA announcement <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/philips-respironics-inc-recalls-trilogy-evo-continuous-ventilators-due-software-related-possible" rel="noreferrer noopener">states</a> that this recall&nbsp;involves correcting devices and does not involve removing them.&nbsp;The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40008191/philips-backs-annual-guidance-on-higher-q2-earnings-despite-china-weakness" rel="noreferrer noopener">Philips Backs Annual Guidance On Higher Q2 Earnings Despite China Weakness</a>
In March, Philips Respironics <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/philips-respironics-inc-recalls-trilogy-evo-continuous-ventilators-due-software-related-possible" rel="noreferrer noopener">notified</a> customers to update the latest software related to Trilogy Evo continuous ventilator devices due to a possible power malfunction. Due to a software issue, these ventilators can issue a &#8220;Battery Depleted&#8221; or &#8220;Loss of Power&#8221; alarm while sufficient power is still available, resulting in a sudden loss of ventilation while the device alarms.
The company is asking users to install a software update to fix problems, including false power loss alarms, an inaccurate display of the amount of oxygen delivered to the patient, and oxygen volume measurement inaccuracies.&nbsp;
Philips is also now requiring the use of filters with the devices to prevent environmental contamination.
There have been nine reported injuries. There has been one reported death. The action affects 90,905 units worldwide.
In August 2023, Philips recalled Respironics Trilogy Evo, Evo O2, EV300, and Evo Universal ventilators after detecting dust and dirt from the environment in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/08/33853091/philips-recalls-faulty-ventilators-fda-identifies-dust-issue-as-most-serious" rel="noreferrer noopener">air path of some devices</a>.
In April, the Dutch medical technology firm reached a $1.1 billion settlement in the U.S.&nbsp;related to&nbsp;the recall of&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38488808/philips-reaches-1-1b-settlement-on-us-sleep-apnea-devices-claims-backs-annual-guidance" rel="noreferrer noopener">its Respironics ventilators</a>.
Price Action: PHG stock is down 1.11% at $32.10 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41169892/blue-shield-of-california-slashes-humira-biosimilar-prices-in-landmark-deal" target="_blank" rel="noreferrer noopener">Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal</a>.</li>
</ul>
Photo by Mats Wiklund via Shutterstock

Large Cap

Health Care

Philips Issues Software Fix For Some Ventilators To Fix Power Alarms Issues, Oxygen Display Errors

Jefferies analyst Dushyant Ailani maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Hold and lowers the price target from $2.2 to $2.

PLUG

Jefferies Maintains Hold on Plug Power, Lowers Price Target to $2

Benzinga's options scanner just detected over 9 options trades for DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) summing a total amount of $1,172,846.
At the same time, our algo caught 5 for a total amount of 257,022.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $34.0 and $60.0 for DraftKings, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for DraftKings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across DraftKings's significant trades, within a strike price range of $34.0 to $60.0, over the past month.
<h3>DraftKings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727979403_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.83</td>
<td>$2.74</td>
<td>$2.83</td>
<td>$60.00</td>
<td>$849.0K</td>
<td>3.2K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$34.00</td>
<td>$92.7K</td>
<td>215</td>
<td style="text-align: right;">244</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.47</td>
<td>$2.46</td>
<td>$2.46</td>
<td>$39.00</td>
<td>$50.6K</td>
<td>2.1K</td>
<td style="text-align: right;">354</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$2.36</td>
<td>$2.19</td>
<td>$2.18</td>
<td>$37.00</td>
<td>$43.6K</td>
<td>205</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$2.5</td>
<td>$2.46</td>
<td>$2.46</td>
<td>$39.00</td>
<td>$35.1K</td>
<td>2.1K</td>
<td style="text-align: right;">147</td>
</tr>
</tbody>
</table>

<h3>About DraftKings</h3>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 27 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
After a thorough review of the options trading surrounding DraftKings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of DraftKings</h3>
<ul>
<li>With a trading volume of 3,154,055, the price of DKNG is up by 0.54%, reaching $37.88.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 28 days from now.</li>
</ul>
<h3>What The Experts Say On DraftKings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $54.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on DraftKings, which currently sits at a price target of $58. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $60. 
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Overweight with a new price target of $47. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on DraftKings, maintaining a target price of $48. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $60. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DraftKings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

DKNG

DraftKings's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ENPH, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Enphase Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $69,550, and 9, calls, for a total amount of $482,823.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $170.0 for Enphase Energy, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Enphase Energy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Enphase Energy's whale activity within a strike price range from $80.0 to $170.0 in the last 30 days. 
<h3>Enphase Energy 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727979397_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$22.0</td>
<td>$21.0</td>
<td>$22.0</td>
<td>$90.00</td>
<td>$99.0K</td>
<td style="text-align: right;">249</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$13.5</td>
<td>$12.45</td>
<td>$12.77</td>
<td>$100.00</td>
<td>$79.1K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$29.0</td>
<td>$26.6</td>
<td>$27.82</td>
<td>$135.00</td>
<td>$69.5K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$21.9</td>
<td>$21.2</td>
<td>$21.6</td>
<td>$90.00</td>
<td>$64.7K</td>
<td style="text-align: right;">249</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.0</td>
<td>$21.0</td>
<td>$21.0</td>
<td>$95.00</td>
<td>$52.5K</td>
<td style="text-align: right;">86</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Enphase Energy</h3>
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Having examined the options trading patterns of Enphase Energy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Enphase Energy</h3>
<ul>
<li>Currently trading with a volume of 917,790, the ENPH's price is down by -2.24%, now at $105.83. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 21 days.</li>
</ul>
<h3>What The Experts Say On Enphase Energy</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $114.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Market Perform rating on Enphase Energy, which currently sits at a price target of $114. 
&#x2A; Reflecting concerns, an analyst from Jefferies lowers its rating to Hold with a new price target of $115.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enphase Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ENPH

Looking At Enphase Energy's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CCJ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 12 options trades for Cameco.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 41%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $27,600, and 11, calls, for a total amount of $458,813.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $60.0 for Cameco over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Cameco options trades today is 4939.0 with a total volume of 3,026.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Cameco's big money trades within a strike price range of $40.0 to $60.0 over the last 30 days.
<h3>Cameco Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727979392_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$60.00</td>
<td>$154.2K</td>
<td>869</td>
<td style="text-align: right;">516</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$2.83</td>
<td>$2.9</td>
<td>$55.00</td>
<td>$43.5K</td>
<td>17.0K</td>
<td style="text-align: right;">153</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.44</td>
<td>$1.43</td>
<td>$1.44</td>
<td>$55.00</td>
<td>$39.7K</td>
<td>4.6K</td>
<td style="text-align: right;">310</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.65</td>
<td>$10.5</td>
<td>$10.65</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>2.8K</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.95</td>
<td>$9.75</td>
<td>$10.3</td>
<td>$50.00</td>
<td>$30.9K</td>
<td>2.8K</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
<h3>Cameco's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,277,193, with CCJ's price up by 0.93%, positioned at $49.9.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cameco options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Cameco's Options: A Look at What the Big Money is Thinking

<a href="https://www.bloomberg.com/news/articles/2024-10-03/tesla-plans-783-million-debt-sale-backed-by-prime-leases?srnd=all" title="https://www.bloomberg.com/news/articles/2024-10-03/tesla-plans-783-million-debt-sale-backed-by-prime-leases?srnd=all">https://www.bloomberg.com/news/articles/2024-10-03/tesla-plans-783-million-debt-sale-backed-by-prime-leases?srnd=all</a>

TSLA

'Tesla Plans $783 Million Debt Sale Backed by Prime Leases' - Bloomberg

Franklin Templeton, a multi-trillion dollar asset management firm, has filed for a new <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">exchange-traded fund</a> (ETF) that would provide exposure to both Bitcoin and Ethereum.
According to an application with the U.S. Securities and Exchange Commission (SEC) on Wednesday, the firm <a href="https://www.sec.gov/files/rules/sro/cboebzx/2024/34-101233.pdf">aims</a> to offer investors a single product that tracks the performance of the two largest cryptocurrencies by market capitalization.
<h3 class="wp-block-heading">A New Index ETF On The Horizon</h3>
The Oct. 2 filing reveals Franklin Templeton&#8217;s intention to launch an index fund that encompasses both Bitcoin and Ethereum. An index fund typically tracks the performance of a collection of assets—such as stocks, bonds, or cryptocurrencies—enabling investors to gain exposure to these assets without directly owning them. 
In this case, the proposed ETF would specifically target Bitcoin and Ethereum, allowing investors to benefit from the movement of these leading cryptocurrencies.
If approved, the new Franklin Templeton Bitcoin and Ethereum Crypto Index ETF will be traded on the Chicago Board Options Exchange (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>).
Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), one of the largest custodians in the United States, is set to handle the fund&#8217;s cash and cash equivalents, while Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) will act as the custodian for the Bitcoin and Ethereum tokens within the fund.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41163889/save-ross-ulbricht-how-donald-trump-got-interested-in-the-imprisoned-silk-road-founder">&#8216;Save Ross Ulbricht!&#8217; How Donald Trump Got Interested In The Imprisoned Silk Road Founder</a>
A notable aspect of this offering is that the fund will be sold in large increments, specifically in blocks of 50,000 shares. 
The product's Net Asset Value (NAV) will be used to determine the share price. Additionally, the index fund will be benchmarked against the CF Institutional Digital Asset Index, which tracks the market performance of both Bitcoin and Ethereum.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
<h3 class="wp-block-heading">Expanding Franklin Templeton&#8217;s Crypto Reach</h3>
This filing marks a potential expansion of Franklin Templeton's involvement in the cryptocurrency space. 
The asset manager already provides clients with exposure to spot Bitcoin and <a href="https://www.benzinga.com/money/what-is-ethereum-etf#:~:text=A%20Spot%20Ethereum%20ETF%20could,stable%20prices%20and%20reduced%20volatility.">Ethereum ETFs</a>, highlighting its ongoing interest in broadening its crypto-based offerings.
Interestingly, this ETF filing comes just hours after Franklin Templeton announced a collaboration with the Aptos Foundation to launch its on-chain U.S. Government Money Market Funds (FOBXX). 
This product gives investors access to FOBXX through the purchase of the BENJI (CRYPTO: BENJI) token, showcasing the firm's diversified approach to integrating blockchain technology into traditional finance products.
<h3 class="wp-block-heading">BNY Mellon&#8217;s Role In The ETF</h3>
Bank of New York Mellon is poised to play a significant role in this potential ETF, as the institution will receive its first ETF custody duties following a non-objection letter from the SEC.
This regulatory clearance allows BNY Mellon to hold digital assets, with an initial focus on Bitcoin and Ethereum ETFs. 
While this exemption was granted with certain conditions, SEC Chairman Gary Gensler has indicated that BNY Mellon could expand its digital asset custody services if it adheres to specific guidelines.
For those interested in the intersection of traditional finance and digital assets, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on November 19 will provide further insights and discussions with industry experts.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41161014/trump-vs-harris-who-do-voters-trust-more-to-handle-crypto-policies">Trump Vs. Harris: Who Do Voters Trust More To Handle Crypto Policies?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

CBOE

COIN

Franklin Templeton Seeks SEC Approval For Dual Bitcoin, Ethereum Index ETF

AUD/NZD is one I'm looking at for an RBA/RBNZ play.
We've seen the kiwi side weakening as lots of banks are calling a 50bp cut at the RBNZ meeting next week (9th October).
There's pros and cons to those calls.
Pro's Their rate is still relatively high vs everyone else (5.25%). Inflation is back at target. They noted weakening economic factors.
Cons The RBNZ have said they will take a "careful and measured" approach to cuts They want to stay restrictive to keep inflation expectations where they are, and that's their "single focus". They say there's still things pointing to positive econ growth, so they feel cuts are more to "remove restraint than provide stimulus".
Overall, the RBNZ haven't come across more dovish to an extent that would lead them to 50bp cuts, and I'm thinking the market may be getting a bit too dovish.
But, this is central banking so no one is going to rule a 50bp cut out after the Fed.
For the trade set up, these expectations for a 50 are being priced in so there's a positive for the trade risk in that If a 50 is expected, a 50 won't be a shock if they drop one. That favours my thinking for being short AUDNZD. On the RBA side, I still hold the view that they will be forced to cut sooner than they think and are telling everyone. We've already had one shift of pushing a hike further away, the next will be data pointing to them cutting. There may be a Bailey styled flip in the pipeline (probably not soon though).
My plan is to get in short AUDNZD and run it over the RNBZ. If the market is expecting 50 and they go a 25, that should get the trade off to a good start and then perhaps I can stay in it to catch an RBA turn.
Obviously lots can happen between events, and AUD is likely to remain strong while the China hopium trade continues.
I'd like AUDNZD a bit higher to start getting in. Ideally up near the last highs around 1.1150's would look tempting, otherwise I might start nibbling small pieces around this 1.10-1.1050 area.<a href="https://www.forexanalytix.com/blog/wp-content/uploads/2024/10/AUDNZD_2024-10-03_14-16-18.png"></a>
There's obvious risks that they have seen a material change in the economy and inflation indicators since their last meeting, and they could well come out far more dovish. That's a risk I'll factor into my trading risk parameters and trade management. If I'm wrong, I'll be wrong on my terms. Like all my trades, I'll be focused on the risk before I focus on any profit.
Ryan Littlestone
Forex Analytix 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="618" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-1024x618.png" alt="" class="wp-image-1852" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-1024x618.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-300x181.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-768x463.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

How Will AUD/NZD Trade On A 25bp Or 50bp Rate Cut From The RBNZ?

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously untreated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41160742/calquence-acalabrutinib-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-" rel="noreferrer noopener">mantle cell lymphoma (MCL)</a>.
The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the first quarter of 2025.
MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), resulting when B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41050339/astrazenecas-top-selling-cancer-drug-tagrisso-receives-fda-green-light-for-another-lung-cancer-in" rel="noreferrer noopener">AstraZeneca&#8217;s Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication</a>.
It is estimated that more than 27,500 people are living with MCL worldwide.
Results from the <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2024%2Fcalquence-acalabrutinib-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percentage-vs-standard-of-care-in-patients-with-untreated-mantle-cell-lymphoma-in-echo-phase-iii-trial.html&amp;esheet=54130935&amp;newsitemid=20241003958806&amp;lan=en-US&amp;anchor=ECHO+Phase+III+trial&amp;index=1&amp;md5=3837bcbd9ded15f0ec3b2c2476b8d102" rel="noreferrer noopener">ECHO Phase III trial</a> recently were presented during the late-breaking oral session at the European Hematology Association (EHA) 2024 Hybrid Congress.
In the trial, Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care (SoC) chemoimmunotherapy.
Adding Calquence to SoC provided almost 1.5 years of additional median progression-free survival (mPFS) with mPFS of 66.4 months for patients treated with the Calquence combination versus 49.6 months with SoC.
Overall survival (OS) showed a favorable trend for the Calquence combination compared to SoC chemoimmunotherapy.
The OS data were not mature during this analysis, and the trial will continue to assess OS as a key secondary endpoint.
The ECHO trial was conducted during the COVID-19 pandemic. After censoring COVID-19 deaths, the PFS was further improved in both arms, with the CALQUENCE combination reducing the risk of disease progression or death by 36%. A favorable trend was seen for OS in this analysis for the Calquence combination, but OS data were not mature.
Price Action: AZN stock is down 1.73% at $78.21 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41170239/american-tower-boosts-data-power-new-400g-aws-connections-to-fuel-ai-and-big-data-at-key-us-data" target="_blank" rel="noreferrer noopener">American Tower Boosts Data Power: New 400G AWS Connections To Fuel AI And Big Data At Key US Data Centers</a>.</li>
</ul>

Biotech

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review

Philadelphia's own Gillie Da King has officially made his mark on the Pennsylvania cannabis market with the launch of Gillie Grows by Insa. Since its debut on September 27, the exclusive line of cannabis strains has captivated consumers at Restore Dispensaries and is now expanding to additional retailers across the state.
Gillie Da King, a prominent influencer and cannabis connoisseur, partnered with Massachusetts-based cannabis brand Insa to develop three unique strains: Purp 30, Mule Kick and Gillie W'nka. Each strain reflects Gillie's personal taste and dedication to high-quality cannabis, combining distinctive flavors, aromas, and effects for an exceptional user experience.
<h2 class="wp-block-heading">Gillie's Personal Touch On Every Strain</h2>
For Gillie Da King, the opportunity to create a line of cannabis strains was a dream come true. "Having the opportunity to put my personal touch on the conceptualization of these strains was a dream! These strains are top-notch, just like everything Insa cultivates in Pennsylvania. Trust me, the people are going to love it!&#8221; he shared.
The strains are a product of close collaboration with Insa's head grower, Kevin Sparks, who praised the partnership: "We combined our expertise and passion to develop these unique strains. From the handpicked terpenes and flavors to the effects Gillie loves, every detail was crafted to deliver a cannabis experience that matches exactly what Gillie looks for in his favorite strains."
<h2 class="wp-block-heading">The Three Strains: Purp 30, Mule Kick And Gillie W'nka</h2>
The Gillie Grows by Insa line includes:
<ul>
<li>Mule Kick: A hybrid with sweet and sour fruit flavors and a hint of diesel, offering balanced effects that help patients relax without feeling overly tired.</li>
<li>Purp 30: An indica-leaning hybrid featuring creamy grape and earthy gas flavors, providing relaxation for any time of day.</li>
<li>Gillie W'nka: A fruity and creamy hybrid designed for a smooth, relaxing experience that patients have praised for managing anxiety and chronic pain.</li>
</ul>
<h2 class="wp-block-heading">A Partnership Built On Loyalty And Expertise</h2>
Gillie's relationship with Restore Dispensaries made the partnership a natural fit, according to Taylor Shields, director of marketing for Restore. "Gillie has been a longtime patient of Restore, and we're honored to be the first retailer to showcase his unique product line. As an independently owned dispensary group, it's important to us that we work with loyal partners like Insa, whose mission aligns with ours."
The exclusive Gillie Grows by Insa strains continue to roll out to additional retailers across Pennsylvania, with cannabis enthusiasts and medical patients eager to experience the new products.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cannabis

Retail Sales

Rapper Gillie Da King Launches Exclusive Cannabis Strains: Here's Where To Find Them

On Thursday, Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) announced its new Visa Tokenized Asset Platform (VTAP). It is designed to help financial institutions issue and manage fiat-backed tokens on blockchain networks, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41162006/visa-introduces-the-visa-tokenized-asset-platform" rel="noreferrer noopener">bridging existing fiat currencies with blockchain technology.</a>
BBVA has been testing core VTAP functionalities this year, including issuing, transferring, and redeeming a bank token on a testnet blockchain. They aim to launch an initial pilot with select customers on the public Ethereum blockchain in 2025.
&#8220;Visa has been at the forefront of digital payments for nearly sixty years, and with the introduction of VTAP, we are once again setting the pace for the industry,&#8221; said Vanessa Colella, Global Head of Innovation and Digital Partnerships of Visa.
Visa&#8217;s VTAP allows banks to safely and efficiently bring fiat currencies onto blockchain networks.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122002/playbux-ceo-envisions-web3-future-where-crypto-is-earned-via-gaming-shopping" rel="noreferrer noopener"> Playbux CEO Envisions Web3 Future Where Crypto Is Earned Via Gaming, Shopping</a>
It offers easy integration with minimal technical setup through accessible APIs, enabling banks to mint and transfer fiat-backed tokens.
VTAP supports programmability, allowing banks to use smart contracts to automate workflows and transactions.
Additionally, it promotes interoperability across various blockchains, facilitating secure cross-chain exchanges of tokenized real-world assets.
&#8220;This collaboration marks a significant milestone in our exploration of the potential of blockchain technology and will ultimately help enable us to broaden our banking services and expand the market with new financial solutions,&#8221; said Francisco Maroto, Head of Blockchain and Digital Assets, BBVA.
Price Action: V shares are trading lower by 0.26% to $276.69 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41060712/trump-wants-nancy-pelosi-prosecuted-over-husband-pauls-visa-stock-sale-before-doj-lawsuit-you-th" target="_blank" rel="noreferrer noopener">Trump Wants Nancy Pelosi Prosecuted Over Husband Paul&#8217;s Visa Stock Sale Before DOJ Lawsuit: &#8216;You Think It Was Luck? I Don&#8217;t Think So&#8217;</a></li>
</ul>
Photo via Shutterstock

Movers

Visa Teams Up with BBVA To Issue Fiat-Backed Tokens On Blockchain Networks, Plans Initial Pilot By 2025

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and raises the price target from $125 to $195.

CVNA

Citigroup Maintains Neutral on Carvana, Raises Price Target to $195

CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher on Thursday. The company disclosed an expansion of the CrowdStrike Marketplace, a hub for top-tier security products compatible with CrowdStrike.
This move enhances the Marketplace Private Offer program, allowing solution providers to engage with CrowdStrike Falcon-integrated technologies.
The Marketplace enables customers to easily discover, try, and purchase leading solutions from their preferred partners while integrating more cybersecurity solutions with the CrowdStrike Falcon platform.
CrowdStrike Marketplace, which was initially launched in the third-quarter of 2023, helps customers optimize cybersecurity investments and enhance the Falcon platform.
Daniel Bernard, chief business officer, CrowdStrike said, &#8220;Over the last year, the Marketplace has taken flight, aligning our entire ecosystem from ISV to solution providers and resellers around CrowdStrike customers with Falcon-integrated solutions that support our mission to stop breaches.&#8221;
&#8220;With the addition of top global and national resellers, we&#8217;re expanding access to leading ISVs, strengthening the Marketplace&#8217;s role in aligning the cybersecurity ecosystem around customer success.&#8221;
Last month, CrowdStrike launched AI Security Posture Management and Data Security Posture Management, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40925721/crowdstrike-launches-ai-security-posture-management-to-enhance-cloud-protection" rel="noreferrer noopener">enhancing its Falcon Cloud Security platform</a>.
Also,&nbsp;the company disclosed a partnership with&nbsp;Dazz to strengthen visibility and protection within CrowdStrike Falcon Cloud Security by <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40915550/crowdstrike-partners-with-dazz-to-streamline-cloud-security-launches-financial-services-subsidia" rel="noreferrer noopener">incorporating&nbsp;Dazz&#8217;s security remediation insights</a>.
Investors can gain exposure to the stock via&nbsp;TrueShares Technology, AI &amp; Deep Learning ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRNZ#NYSE">LRNZ</a>), and&nbsp;REX AI Equity Premium Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NYSE">AIPI</a>).
Price Action: CRWD shares are up 1.31% at $283.92 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances" target="_blank" rel="noreferrer noopener">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating: &#8216;Deeply Sorry This Happened&#8217;</a></li>
</ul>

AIPI

CRWD

LRNZ

CrowdStrike Expands Marketplace, Falcon-Integrated Solutions Boost Cybersecurity Ecosystem

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Levi Strauss, revealing an average target of $24.33, a high estimate of $26.00, and a low estimate of $21.00. A 3.34% drop is evident in the current average compared to the previous average price target of $25.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978514_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Levi Strauss among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Levi Strauss. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Levi Strauss compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Levi Strauss's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Levi Strauss's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LEVI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Levi Strauss analyst ratings.</a>
<h2>About Levi Strauss</h2>
Levi Strauss &amp; Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss &amp; Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
<h3>Levi Strauss: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Levi Strauss's remarkable performance in 3 months is evident. As of 31 May, 2024, the company achieved an impressive revenue growth rate of 7.81%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Levi Strauss's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.25% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Levi Strauss's ROE stands out, surpassing industry averages. With an impressive ROE of 0.92%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Levi Strauss's ROA stands out, surpassing industry averages. With an impressive ROA of 0.3%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.12.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LEVI

Analyst Scoreboard: 6 Ratings For Levi Strauss

In the last three months, 11 analysts have published ratings on Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $17.68, with a high estimate of $23.00 and a low estimate of $9.50. This current average has decreased by 3.55% from the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978505_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Riot Platforms among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Bill Papanastasiou</td>
<td>Stifel</td>
<td>Announces</td>
<td>Speculative Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Riot Platforms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Riot Platforms compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Riot Platforms's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RIOT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Riot Platforms analyst ratings.</a>
<h2>Unveiling the Story Behind Riot Platforms</h2>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.
<h3>Riot Platforms: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Riot Platforms's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -8.76% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Riot Platforms's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -120.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Riot Platforms's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.34%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Riot Platforms's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.17%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Riot Platforms adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIOT

The Latest Analyst Ratings For Riot Platforms

Truist Securities analyst Michael Ciarmoli maintains Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) with a Buy and lowers the price target from $101 to $91.

Truist Securities Maintains Buy on Albany Intl, Lowers Price Target to $91

In the preceding three months, 20 analysts have released ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $992.05, a high estimate of $1125.00, and a low estimate of $884.00. Witnessing a positive shift, the current average has risen by 7.74% from the previous average price target of $920.74.
<img src="https://www.benzinga.com/files/images/story/2024/1727978449_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1100.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Peter Verdult</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$1060.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1106.00</td>
<td>$1106.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$1030.00</td>
<td>$884.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1101.00</td>
<td>$1001.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1125.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$884.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$913.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Eli Lilly's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>Discovering Eli Lilly: A Closer Look</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Eli Lilly's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 35.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's net margin excels beyond industry benchmarks, reaching 26.25%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 22.5%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eli Lilly's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eli Lilly's debt-to-equity ratio is below the industry average. With a ratio of 2.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Eli Lilly

Throughout the last three months, 10 analysts have evaluated NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $58.7, with a high estimate of $66.00 and a low estimate of $46.00. This current average has decreased by 7.47% from the previous average price target of $63.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978439_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of NEXTracker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dimple Gosa</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NEXTracker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for NEXTracker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into NEXTracker's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NXT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NEXTracker analyst ratings.</a>
<h2>About NEXTracker</h2>
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
<h3>NEXTracker: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: NEXTracker's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 50.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: NEXTracker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NEXTracker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): NEXTracker's ROA stands out, surpassing industry averages. With an impressive ROA of 4.73%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NEXTracker's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss NEXTracker Stock

In the last three months, 18 analysts have published ratings on Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Shoals Technologies Gr and provided 12-month price targets. The average target is $10.25, accompanied by a high estimate of $23.00 and a low estimate of $4.00. This current average represents a 16.6% decrease from the previous average price target of $12.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978427_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Shoals Technologies Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Donovan Schafer</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Shoals Technologies Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Shoals Technologies Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Shoals Technologies Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Shoals Technologies Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Shoals Technologies Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Shoals Technologies Gr</h2>
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
<h3>A Deep Dive into Shoals Technologies Gr's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Shoals Technologies Gr's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -16.74%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Shoals Technologies Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Shoals Technologies Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.15% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Shoals Technologies Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.46%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.27, Shoals Technologies Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF

매도 수량

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF (ARCA:FCFY), 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌